Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 PRM-151 trial in idiopathic pulmonary fibrosis
NL-OMON43714Phase 2Active, not recruiting
- Sponsor
- Promedior
- Start
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing PRM-151 with Placebo (2 arms). Primary endpoint: Mean change in FVC percent predicted. Started Sep 2015; status: active, not recruiting.
02
Drugs
zinpentraxin alfa
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON43714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43714.